ETV6 (Human) Recombinant Protein (P01)
- Known as:
- ETV6 (Human) Recombinant Protein (P01)
- Catalog number:
- H00002120-P01-25
- Product Quantity:
- 25 ug
- Category:
- -
- Supplier:
- Abno
- Gene target:
- ETV6 (Human) Recombinant Protein (P01)
Related genes to: ETV6 (Human) Recombinant Protein (P01)
- Gene:
- BZW2 NIH gene
- Name:
- basic leucine zipper and W2 domains 2
- Previous symbol:
- -
- Synonyms:
- HSPC028, MST017, MSTP017
- Chromosome:
- 7p21.1
- Locus Type:
- gene with protein product
- Date approved:
- 2002-08-05
- Date modifiied:
- 2016-10-05
- Gene:
- C2CD3 NIH gene
- Name:
- C2 calcium dependent domain containing 3
- Previous symbol:
- -
- Synonyms:
- DKFZP586P0123
- Chromosome:
- 11q13.4
- Locus Type:
- gene with protein product
- Date approved:
- 2007-10-17
- Date modifiied:
- 2016-06-08
- Gene:
- ETV6 NIH gene
- Name:
- ETS variant 6
- Previous symbol:
- -
- Synonyms:
- TEL
- Chromosome:
- 12p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-28
- Date modifiied:
- 2019-04-23
- Gene:
- MBTD1 NIH gene
- Name:
- mbt domain containing 1
- Previous symbol:
- -
- Synonyms:
- SA49P01, FLJ20055
- Chromosome:
- 17q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 2003-01-15
- Date modifiied:
- 2015-04-21
- Gene:
- TMEM63C NIH gene
- Name:
- transmembrane protein 63C
- Previous symbol:
- C14orf171
- Synonyms:
- DKFZp434P0111, CSC1, hsCSC1
- Chromosome:
- 14q24.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-12-10
- Date modifiied:
- 2017-10-17
Related products to: ETV6 (Human) Recombinant Protein (P01)
Related articles to: ETV6 (Human) Recombinant Protein (P01)
- While ETV6::RUNX1-positive acute lymphoblastic leukemia (ALL) is generally associated with favorable outcomes, a subset of patients experience relapse despite receiving standard therapy, underscoring the need for early biomarkers to identify high-risk subgroups. In this retrospective study of 345 consecutive pediatric patients with ETV6::RUNX1-positive ALL treated in accordance with the protocol of the Chinese Children's Leukemia Group (CCLG-ALL 2008), CD33 expression (CD33) on leukemic blasts was detected in 55.9% of patients and was significantly associated with minimal residual disease (MRD) positivity on day 15 (D15-MRD-positive) (65.2% vs. 42.0%, P < 0.001). Multivariate analysis revealed CD33 status as an independent risk factor for D15-MRD positivity (odds ratio (OR) = 2.66, 95% confidence interval (CI) 1.66-4.26). Among CD33 patients, those who were D15-MRD-positive had significantly inferior 5-year and 10-year event-free survival (EFS) relative to those who were D15-MRD-negative (5-year EFS: 91.9% ± 2.4% vs. 100%, P = 0.027; 10-year EFS: 89.2% ± 3.0% vs. 100%, P = 0.014). This prognostic association was not observed in CD33-negative patients. In conclusion, the combination of CD33 and D15-MRD-positivity may identify a distinct high-risk subgroup within ETV6::RUNX1-positive ALL. Early intervention, potentially including CD33-directed therapy, may represent a promising strategy to improve outcomes in this subgroup, although further validation is warranted. - Source: PubMed
Publication date: 2026/05/29
Zheng XuelingLuo YuxiZhang RuidongLiu XiaohangHuang PengliGao ChaoChen HuiFan JiaLin WeiYu JiaoleZhang YuanyuanQi PeijingWu YingZhao XiaoxiLi JunPeng XiaoxiaWang TianyouZheng Huyong - Secretory carcinoma (SC) is a rare salivary gland neoplasm characterized by the ETV6::NTRK3 gene fusion, and it has been recognized as a distinct entity in the World Health Organization Classification of Head and Neck Tumors since 2017. Case 1 involved a 21-year-old Japanese man who presented with a 1-year history of a slow-growing, painless mass in the right parotid gland. Ultrasonography and magnetic resonance imaging demonstrated a well-circumscribed, homogeneous tumor measuring 16x12x10 mm. The patient underwent superficial parotidectomy. Case 2 involved a 79-year-old Japanese man who noticed a mass in the right parotid region 3 weeks before presentation. Imaging studies revealed a tumor with irregular margins and heterogeneous internal features, measuring 21x16x15 mm. The patient underwent total parotidectomy with selective neck dissection. Histological examination revealed features consistent with SC in both cases. Immunohistochemically, the tumor cells were positive for S-100 protein, mammaglobin and cytokeratin 7. The diagnosis was further supported by detection of the ETV6::NTRK3 gene fusion using reverse transcription-polymerase chain reaction and Sanger sequencing. Both patients received postoperative radiotherapy at a total dose of 60 Gy. No evidence of local recurrence or distant metastasis has been observed during the follow-up period of 7 years in case 1 and 3 years in case 2. - Source: PubMed
Publication date: 2026/05/07
Hayashi MisakiBandoh NobuyukiGoto TakashiHayashi ShutoArima RyotaNakamuta KokiIsochi-Yamaguchi TomomiBaba ShogoKato YasutakaTakahara MikiTakei Hidehiro - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy and genomic profiling has become increasingly vital for risk stratification. We conducted a retrospective single-center study including 96 newly diagnosed pediatric patients with ALL and mixed phenotype acute leukemia to characterize the genomic landscape using conventional and molecular cytogenetics, multiplex ligation-dependent probe amplification and targeted next-generation sequencing and to evaluate associations with treatment response and survival. Mutation co-occurrence analysis revealed a NRAS/KRAS/JAK cluster and an :: cluster characterized by relative mutational exclusivity, with additional associations between - and -CCND3 alterations. Del alterations showed a trend toward higher day-15 minimal residual disease (MRD) levels and inferior 2-year event free survival rate (EFS). Del-positive cases showed lower 2-year EFS. In contrast, :: and high hyperdiploidy were associated with favorable early response and EFS. Del did not independently influence outcome. positive cases showed higher early MRD levels despite excellent survival outcomes. NRAS/KRAS mutations were significantly associated with higher positive day-15 MRD (Wilcoxon, = 0.0067) and remained independently associated after adjustment for white blood cell count and cytogenetic subgroup. Intermediate risk (IR) and high-risk groups showed comparable 2-year EFS, indicating limited discrimination by conventional risk stratification. The IR group displayed a heterogeneous genomic profile, with NRAS/KRAS, Ph-like mutations and del among the most frequent alterations. These observations highlight the potential of integrated genomic profiling to refine risk stratification, particularly by identifying clinically relevant subgroups within the IR category. - Source: PubMed
Publication date: 2026/05/18
Stefan-Hodorogea AndreeaRadu LetitiaMarcu AndraSerbanica AndreeaBica AnaJercan CristinaMarcu AnaJardan DumitruJardan CeraselaCalugaru OndaDragomir MihaelaPopa CodrutaGheorghe AncaVihta KarinaDima SimonaColita Anca - Non-intestinal type sinonasal adenocarcinomas (non-ITACs) are rare entities with a wide range of histologic appearances. In this study we characterize the clinico-pathologic, immunohistochemical and molecular features of six cases of sinonasal adenocarcinoma with clear cell morphology, identified retrospectively in our files and occurring in 2 females and 4 males, with mean age of 62.6 years. Immunohistochemical and molecular studies including RNA sequencing, were performed. All cases showed a proliferation of epithelioid clear cells with slight to moderate atypia, arranged in variable patterns. Two cases had the typical histologic appearance and immunohistochemical profile of sinonasal renal cell-like adenocarcinoma, being formed of follicular structures and solid nests containing eosinophilic colloid-like material, with diffuse positivity for SOX10, carbonic anhydrase IX (CAIX), S100, and cytokeratin 7. One further case had a similar histologic appearance but lacked positivity for CAIX and S100. A previously unreported ETV6::YEATS4 rearrangement was detected by RNA sequencing in this case. Two adenocarcinomas showed mixed tubulo-papillary and acinar architecture with clear cell foci, including areas reminiscent of renal cell-like adenocarcinoma. Finally, one case had a tubulo-cystic appearance with clear cells and a surface component presenting ciliated, papillary and squamoid areas. This adenocarcinoma presented a MAP2K1 p.Gln56Pro; c.167 A > C mutation. Immunohistochemically, all cases were strongly positive for pancytokeratin and cytokeratin 7, SOX10 was positive in all cases tested (5/5), whereas S100 was positive in 4/6 cases and DOG1 in 1/3 cases. Notably, basal/myoepithelial markers and renal cell carcinoma markers, including CD10, PAX8 and RCC, were negative in all cases. Sinonasal adenocarcinomas with clear cell features are a heterogenous group of neoplasms in the spectrum of low-grade non-ITAC that must be differentiated from primary salivary-type sinonasal adenocarcinomas and from metastatic carcinomas. The differential diagnosis requires the support of an immunohistochemical panel, as well as molecular testing in selected cases. - Source: PubMed
Publication date: 2026/05/27
Franchi AlessandroDin Nasir Udvan den Hout MariArcovito GiorgiaDallan IacopoScarpitta RosaStoehr RobertAgaimy Abbas - Mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion is rare, and its clinicopathologic features, genetic landscape, therapeutic response, and patient outcomes remain incompletely defined, as does its relationship to blast-phase chronic myeloid leukemia (CML). In this multicenter study of 44 patients, 86.4% had B/myeloid MPAL, 72.7% showed lymphoid predominance, 40.9% had complex karyotypes (CK), and 68.3% harbored somatic mutations, most commonly RUNX1 mutations (46.3%). RUNX1 mutations frequently co-occurred with AML-associated alterations, whereas DNMT3A, TET2, and BCORL1 mutations were restricted to RUNX1-mutated cases. In contrast, ALL-associated alterations (IKZF1 mutation/deletion and ETV6 mutations) were confined to RUNX1-wild-type patients. TP53 and signaling-pathway mutations (NRAS, KRAS, PTPN11, and FLT3) were not detected. Forty-two patients received induction chemotherapy and/or immunotherapy combined with tyrosine kinase inhibitors: 74.2% of lymphoid-predominant and 63.6% of myeloid-predominant patients receiving ALL- and AML-type therapies, respectively. Ten patients relapsed and 2 had primary refractory disease; some exhibited dynamic shift in predominant lineage immunophenotype, chromosomal alterations, and somatic mutations at relapse or refractory stage. The overall remission rate was 86.8%, with no significant differences across ALL-, AML-, or hybrid-type regimens. After a median follow-up of 24.2 months, the median overall survival (OS) was 52.5 months. CK was associated with inferior OS compared with cases lacking additional chromosomal alterations (p=0.02), whereas RUNX1 mutations were not. No significant differences in genetic profiles, treatment response, or outcomes were observed between patients with and without CML-like features. This study provides a comprehensive genomic and clinical characterization of BCR::ABL1-positive MPAL, supporting improved risk stratification and future therapeutic strategies. - Source: PubMed
Publication date: 2026/05/21
Shen QiudanHuang XiaoyanWang XiaoqiongShuai WenFang HongJabbour ElliasChen WeinaTashakori MehrnooshKhanlari MahsaWu XiaojunShao LinaZhang LingEl Hussein SibaKonoplev SergejKhoury Joseph DTang GuilinWang WeiWang Sa AMedeiros L JeffreyHu Shimin